Clinical trials
Graft Versus Host Disease clinical trials
Below are recruiting graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06663722RecruitingPhase 2
Axatilimab and ECP for chronic graft-versus-host disease
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
San Francisco, CaliforniaAges 12 years+ - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT06649201Recruiting
Study of vaginal health after stem cell transplant
This study looks at how stem cell transplants affect the vagina, especially if you develop a condition called graft-versus-host disease (GVHD). Researchers will examine the vagina and test its natural germs (microbiome) to better understand and possibly improve treatment.
Cleveland, OhioAges 18–70 - NCT06619561RecruitingPhase 2
Testing vimseltinib for chronic graft versus host disease
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Duarte, CaliforniaAges 18 years+ - NCT06615050RecruitingPhase 3
Comparing two drug combinations for stem cell transplant
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Palo Alto, CaliforniaAges 18 years+ - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Birmingham, AlabamaAges 12 years+ - NCT06392711RecruitingPhase 1
Stem cell therapy for dry mouth not from radiation
This trial tests a new treatment using special cells (mesenchymal stromal cells) from your own bone marrow to help with dry mouth that is not caused by radiation. The goal is to see if it can increase saliva production and improve quality of life.
Madison, WisconsinAges 18–90 - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT06300320RecruitingPhase 2
TQ05105 for chronic graft-versus-host disease
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hefei, AnhuiAges 18–70 - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06247150Recruiting
Study of immune cells in graft-versus-host disease after stem cell transplant
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
PessacAges 18 years+ - NCT06186804Enrolling by invitationPhase 2
Study of ABSK021 for chronic graft-versus-host disease
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Stanford, CaliforniaAges 3 years+ - NCT06046248RecruitingPhase 2
Belumosudil and Rituximab for first-time chronic GVHD treatment
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
Atlanta, GeorgiaAges 18 years+ - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+ - NCT05919511Recruiting
Questionnaire study for people at risk after stem cell transplant
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
Birmingham, AlabamaAges 18 years+ - NCT05922761RecruitingPhase 2
Belumosudil for lung scar prevention or treatment after transplant
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Stanford, CaliforniaAges 18 years+ - NCT03819803RecruitingPhase 3
Fecal transplant for gut graft-versus-host disease
This study tests whether restoring healthy gut bacteria using a fecal microbiota transplant can improve steroid-refractory gut graft-versus-host disease (aGvHD) after stem cell transplant. If your gut symptoms are your first episode and your stool bacteria diversity is low, this trial may be an option worth screening for.
Graz, StyriaAges 18–70 - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for graft versus host disease?
- Yes. Clin2 currently lists 122 recruiting graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.